{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T01:26:59Z","timestamp":1747186019167,"version":"3.40.5"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T00:00:00Z","timestamp":1587772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims\/Introduction<\/jats:title><jats:p>Type\u00a02 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long\u2010term treatments are available. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an investigator\u2010initiated multicenter prospective intervention study in which ipragliflozin (50\u00a0mg) was administered once daily, and glycemic control, estimated glomerular filtration rate (eGFR) and adverse events were evaluated until 104 weeks after starting research.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 407 patients analyzed. In the eGFR \u226590 group and eGFR \u226560 to &lt;90 group, eGFR had significantly decreased compared with baseline at all time points from 4 to 104\u00a0weeks. There were significant increases in the eGFR \u226545 to &lt;60 groups compared with baseline at 36\u00a0weeks (2.3\u00a0\u00b1\u00a01.0) and 52\u00a0weeks (2.6\u00a0\u00b1\u00a01.2). Comparison between the eGFR &lt;60, urine albumin\u2010to\u2010creatinine ratio &gt;300 group and the eGFR &lt;60, urine albumin\u2010to\u2010creatinine ratio &lt;300 group showed a greater reduction in eGFR in the former (\u22125.4\u00a0\u00b1\u00a02.4 vs 3.3\u00a0\u00b1\u00a01.1) at 12\u00a0weeks and was maintained to 104\u00a0weeks. In any group, eGFR did not significantly decrease until 104\u00a0weeks compared with 4\u00a0weeks. The urine albumin\u2010to\u2010creatinine ratio after 52\u00a0weeks and after 104\u00a0weeks was significantly decreased compared with baseline in the eGFR \u226590 group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ipragliflozin lowers eGFR and corrects hyperfiltration in patients with high eGFR (eGFR \u226560). In patients with low eGFR (eGFR \u226530 to &lt;60), ipragliflozin has the possibility of increasing eGFR and exerting a renoprotective effect.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdi.13248","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T09:36:08Z","timestamp":1583746568000},"page":"1248-1257","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of ipragliflozin on the development and progression of kidney disease in patients with type\u00a02 diabetes: An analysis from a multicenter prospective intervention study"],"prefix":"10.1111","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4363-5036","authenticated-orcid":false,"given":"Ikuro","family":"Matsuba","sequence":"first","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Kawata","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Iemitsu","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Asakura","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Amemiya","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syogo","family":"Ito","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Kaneshiro","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kanamori","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kubota","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Shinoda","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Takai","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Takuma","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Takihata","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takeda","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Tanaka","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Machimura","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuki","family":"Minagawa","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Minami","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuko","family":"Mokubo","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Miyakawa","sequence":"additional","affiliation":[{"name":"The Study Group of the Diabetes Committee Kanagawa Physicians Association Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-3697","authenticated-orcid":false,"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism Yokohama City University Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Metabolism and Endocrinology Department of Internal Medicine St. Marianna University School of Medicine Kawasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","unstructured":"The Japanese Society for Dialysis Therapy.Current status of dialysis therapy 2017. Available fromhttps:\/\/docs.jsdt.or.jp\/overview\/(Japanese) Accessed August 1 2019.https:\/\/doi.org\/10.4009\/jsdt.51.699.","DOI":"10.4009\/jsdt.51.699"},{"key":"e_1_2_7_3_1","unstructured":"Japanese Society of Nephrology and The Japan Diabetes Society.Strategic action Plan for Diabetic Kidney Disease. Available fromhttps:\/\/cdn.jsn.or.jp\/data\/STOP\u2010DKD.pdf(Japanese) Accessed August 1 2019."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0337-y"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12156"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0169-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-65"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7196"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2875w"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3761"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13620"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30180-9"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2417w"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2492w"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3116w"},{"key":"e_1_2_7_19_1","first-page":"S96","article-title":"Study on effectiveness and safety ASSIGN\u2010K with the SGLT2 inhibitor 104 weeks administration for patients with type 2 diabetes","volume":"33","author":"Kawata T","year":"2018","journal-title":"J Jpn Phys Assoc"},{"key":"e_1_2_7_20_1","first-page":"235","article-title":"Study on effectiveness and safety ASSIGN\u2010K with the ipragliflozin 104 weeks administration for patients with type 2 diabetes","volume":"80","author":"Kawata T","year":"2018","journal-title":"J Constitut Med"},{"key":"e_1_2_7_21_1","first-page":"559","article-title":"Evaluation of the safety and efficacy of SGLT2 inhibitor luseogliflozin in elderly patients with type 2 diabetes mellitus\u2010post\u2010marketing surveillance in elderly patients (final report)","volume":"45","author":"Kurose T","year":"2017","journal-title":"Jpn Pharmacol Ther"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1219341"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12626"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-1320"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.31.433"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2000.16225"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12802"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.203869"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037418"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22229-5"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13017"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035901"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12403"},{"key":"e_1_2_7_35_1","first-page":"357","article-title":"Investigation of the safety and efficacy of dapagliflozin for type 2 diabetes in elderly patients\u2010final report of the dapagliflozin observational study (DIANTHUS study)","volume":"45","author":"Yoshida S","year":"2017","journal-title":"Jpn Pharmacol Ther"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdi.13248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13248","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.13248","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.13248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T05:19:08Z","timestamp":1693891148000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.13248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,25]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/jdi.13248"],"URL":"https:\/\/doi.org\/10.1111\/jdi.13248","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"type":"print","value":"2040-1116"},{"type":"electronic","value":"2040-1124"}],"subject":[],"published":{"date-parts":[[2020,4,25]]},"assertion":[{"value":"2019-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}